Year: 2024
Type: article
Study design: Clinical Trial
Abstract: Objective of the study: to evaluate the effectiveness of progestagen treatment of endometrial hyperplasia (EG) in women of late reproductive age.Materials and methods. 48 patients aged 37–45 with EG were under observation. The EG diagnosis in patients was verified by histological examination. The treatment effectiveness was evaluated based on the results of clinical-instrumental and morphological examination after 6 months of treatment and every 3 months in the dynamics of observation. All patients with EG received dienogest (Vigest-KV) 2 mg once a day continuously for 6 months.Results. 60.4% (29) of women had abnormal uterine bleeding at the time of examination. 39.5% (19) of patients had no pronounced clinical symptoms. Evaluating the effectiveness of the proposed therapy after 6 months of treatment showed that the endometrium thickness was 7.8 ± 0.36 mm on average, which is significantly lower than it was before treatment – 23.0 ± 2.8 mm (p ≤ 0.05). This indicator was practically at the same level after 9 months – 9.4 ± 0.48 mm (p ≥ 0.05). Pipelle biopsy showed that 42 patients (87.5%) experienced regression of the hyperplastic endometrium, and the ratio of stromal and glandular components in histological preparations also normalized. Persistence of the disease was noted in 12.5% (6) of women according to the morphological examination after treatment, EG without atypia was found. In 14.9% (5) of these 42 patients with a regression of the disease were a relapse of the disease according to a pipelle biopsy after 3 months, – EG without atypia was detected. Conclusions. The effectiveness of the proposed therapy in patients with EG in late reproductive age after 6 months was 87.5%, the progression of the disease was not noted, and the relapse rate after 9 months of observation was 11.9%.Thus, dienogest therapy in a continuous long-term regimen in women with EG in late reproductive age showed high clinical and morphological effectiveness due to the powerful antiproliferative effect of the drug.
Source: Reproductive Endocrinology
Author: O.V. Kravchenko
Institution: Bukovinian State Medical University
Language: English
Subfield: Obstetrics and Gynecology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4405947282